Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | AbbVie Inc | 697 |
| 2 | Celgene Corp | 317 |
| 3 | Takeda Pharmaceutical Co Ltd | 231 |
| 4 | AbbVie Biotechnology Ltd | 191 |
| 5 | Abbott Laboratories | 183 |
| 6 | Pfizer Inc | 179 |
| 7 | Purdue Pharma LP | 155 |
| 8 | Allergan Inc | 143 |
| 9 | Biogen MA Inc | 141 |
| 10 | Pfizer Corp SRL | 140 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61K | Medicinal preparations | 10,799 |
| 2 | A61P | Therapeutic activity (drug indications) | 10,148 |
| 3 | C07D | Heterocyclic compounds | 3,569 |
| 4 | C07K | Peptides | 2,207 |
| 5 | Y02A | Climate change adaptation | 1,435 |
| 6 | C12N | Microorganisms, enzymes | 910 |
| 7 | G01N | Investigating / analysing materials | 807 |
| 8 | A61M | Devices for introducing media into the body | 689 |
| 9 | C07C | Acyclic and carbocyclic compounds | 445 |
| 10 | A61L | Sterilising / disinfecting materials | 415 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionMost-cited patents
Patents ranked by forward citations reveal the foundational inventions the field continues to build on.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Method of reducing somnolence in patients treated with tizanidine | 2002 | Acorda Therapeutics Inc | 36 |
| TIZANIDINE SUCCINATE SALT FORMS AND METHODS OF MAKING AND USING THE SAME | 2008 | Transform Pharmaceuticals Inc | 17 |
| A METHOD FOR THE PREPARATION OF TIZANIDINE HYDROCHLORIDE | 2010 | FARMAK, A.S. | 13 |
| Novel use of tizanidine or its derivatives | 2007 | KERUIDE PHARMACEUTICAL CO., LTD., SICHUAN | 11 |
| Green new process for preparing tizanidine hydrochloride | 2011 | CHANGZHOU YABANG PHARMACEUTICAL CO., LTD. | 10 |
Where research is gaining momentum
Research themes ranked by publication activity show where scientific interest is accelerating around this compound.
| # | Research topic | Papers |
|---|---|---|
| 1 | Botulinum Toxin and Related Neurological Disorders | 7 |
| 2 | Migraine and Headache Studies | 4 |
| 3 | Drug-Induced Hepatotoxicity and Protection | 2 |
| 4 | Pharmacogenetics and Drug Metabolism | 2 |
| 5 | Advancements in Transdermal Drug Delivery | 1 |
| 6 | Analytical Methods in Pharmaceuticals | 1 |
| 7 | Anesthesia and Sedative Agents | 1 |
| 8 | Cerebral Palsy and Movement Disorders | 1 |
| 9 | Drug Solubulity and Delivery Systems | 1 |
| 10 | Drug-Induced Ocular Toxicity | 1 |
Technology trend analysis
Cypris uses AI to connect emerging research themes to IP activity, commercialization signals, and underexplored opportunity areas.
See Cypris in actionWho's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Herbert R. Henney | Acorda Therapeutics (United States) | 6 |
| 2 | Hideki Ono | Nagoya City University | 6 |
| 3 | Pertti J. Neuvonen | University of Helsinki | 6 |
| 4 | Janne T. Backman | University of Helsinki | 5 |
| 5 | M.M. Mirbagheri | Shirley Ryan AbilityLab | 5 |
| 6 | Ajit Jadhav | National Center for Advancing Translational Sciences | 4 |
| 7 | Akira Sugimoto | Meijo University | 4 |
| 8 | Anton Simeonov | National Center for Advancing Translational Sciences | 4 |
| 9 | E. Jankowska | University of Gothenburg | 4 |
| 10 | A. Yelnik | Hôpital Fernand-Widal | 3 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review | 2004 | 372 | Parkinson's Disease Mechanisms and Treatments |
| Non-expanded adipose stromal vascular fraction cell therapy for multiple sclerosis | 2009 | 318 | Mesenchymal stem cell research |
| Practice Parameter: Pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review) | 2010 | 299 | Neurological disorders and treatments |
| Treatments for spasticity and pain in multiple sclerosis: a systematic review | 2003 | 267 | Multiple Sclerosis Research Studies |
| Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2 | 2009 | 262 | Pharmacogenetics and Drug Metabolism |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the chemical composition and molecular structure of Tizanidine?
Which organizations hold the most patents related to Tizanidine?
What are the primary research areas associated with Tizanidine based on recent publications?
How has patent activity for Tizanidine evolved in recent years?
What notable patents exist for Tizanidine manufacturing and formulation?